Evidence map›Paper›PMID 40950579›Full record

ArticleFrontiers in microbiology2025

High-yield astaxanthin production process development and scale-up validation from wild-type

Po Chen, Xingli Shi, Jingyan Jiang, Huanghe Cheng, Jinyan Chai, Zhenggang Xie, Mohd Helmi Sani

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Po Chen *Gastroenterology and Urology Department II, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Xingli Shi *T&J Bio-engineering (Shanghai) Co., Ltd., Shanghai, China.
Jingyan JiangT&J Bio-engineering (Shanghai) Co., Ltd., Shanghai, China.
Huanghe ChengT&J Bio-engineering (Shanghai) Co., Ltd., Shanghai, China.
Jinyan ChaiT&J Bio-engineering (Shanghai) Co., Ltd., Shanghai, China.
Zhenggang XieT&J Bio-engineering (Shanghai) Co., Ltd., Shanghai, China.
Mohd Helmi SaniDepartment of Biosciences, Faculty of Sciences, University Technology Malaysia, Skudai, Johor, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study developed an integrated strategy to significantly enhance astaxanthin production from wild-type Methods: The research combined traditional parameter optimization with LSTM (Long Short-Term Memory) intelligent modeling. Systematic optimization of fermentation conditions was conducted in 500 mL bioreactors, followed by scale-up to 5 L systems. An innovative LSTM prediction model was constructed to predict astaxanthin concentration throughout the fermentation process. Results: Optimal fermentation conditions were determined as temperature 20°C, pH 4.5, and dissolved oxygen 20%, achieving an astaxanthin yield of 387.32 mg/L within 144 hours in 500 mL bioreactors. Upon scale-up to 5 L, the yield improved to 400.62 mg/L within 165 hours, demonstrating process robustness. The LSTM prediction model showed excellent performance with R Discussion: This research confirms the feasibility of achieving commercial-scale production of high-value natural astaxanthin through non-genetically modified approaches. The resulting product combines high productivity, safety, and regulatory advantages, providing an innovative solution for industrial-scale natural astaxanthin production that offers significant commercial potential.

Indexed as

astaxanthinfermentation optimizationLSTM modelingPhaffia rhodozymascale-up

Identifiers

PMID40950579
PMCPMC12425955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.